Acurable
Acurable develops wearable medical devices based on proprietary acoustic sensing technology that enable automated home diagnosis and continuous monitoring of respiratory and cardiac conditions, primarily serving sleep clinics, NHS hospitals, US health systems, and pharmaceutical research organizations.
- Company typePrivate
- Founded2016
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Acurable does
Acurable Ltd is a London-based medical device company founded in 2016 as a spin-out from Imperial College London, developing wearable devices that use proprietary acoustic sensing technology to record internal respiratory and cardiac sounds via a non-invasive neck-worn sensor. Recordings are transferred wirelessly to a mobile device and processed in a secure cloud platform by proprietary signal processing algorithms that automatically extract physiological parameters (AHI, ODI, SpO2, cardiac signal, respiratory phases, airflow, snoring, pulse rate, body position) and generate clinically validated diagnostic reports within minutes, without manual specialist interpretation.
The company's product family comprises three AcuPebble devices: SA100 (CE-marked home sleep apnea testing device and the first to receive CE mark for automated diagnosis of Obstructive Sleep Apnoea, also FDA 510(k) cleared in 2021), Ox100 (FDA-cleared 8-channel multi-channel home sleep study device launched in the US in 2023), and RE100 (continuous monitoring device for clinical research and post-market surveillance). The technology platform is positioned for Sleep Apnea, COPD, Epilepsy, and Asthma applications.
Acurable sells hardware to healthcare professionals and health systems through quote-based B2B enterprise contracts, with distribution via direct enterprise sales (NHS hospitals, sleep clinics, US health systems) and channel partners (Nyxoah for Germany). Revenue streams include device sales (SA100/Ox100/RE100) and cloud-based automated diagnosis services. The company has raised approximately €13m+ cumulatively across seed funding, Innovate UK grants, and an October 2022 €11m Series A led by Kibo Ventures with KHP Ventures participation, and operates from London and Seville with expansion into the US market.
Acurable firmographics
Firmographics- Name
- Acurable
- Legal name
- Acurable Ltd
- Website
- https://acurable.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Acurable develops wearable medical devices based on proprietary acoustic sensing technology that enable automated home diagnosis and continuous monitoring of respiratory and cardiac conditions, primarily serving sleep clinics, NHS hospitals, US health systems, and pharmaceutical research organizations.
- Ownership category
- akta.pro rank
Acurable industry classification
Industry- Product category
- Sleep Apnea Diagnostic Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)
- akta.pro secondary industries
- Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Pulmonology & Sleep Medicine Telemedicine Platforms (HLALAGAF), Sleep Tech Wearables (CRACAIAG)
Keywords
Where Acurable is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Acurable business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- AcuPebble SA100 / Ox100 device sales: Sale of wearable medical devices (AcuPebble SA100, AcuPebble Ox100, AcuPebble RE100) to healthcare professionals and health systems. The sensor is multi-use and rechargeable, sold alongside adhesives and accessories. Quote-based pricing for healthcare system procurement.
- Cloud-based automated diagnosis service: Automated signal processing and diagnostic report generation via secure cloud platform. Part of the device ecosystem, potentially as an included or subscription component bundled with device sales.
- Clinical research and post-market surveillance (RE100): AcuPebble RE100 is used in clinical trials and post-market surveillance, sold to pharmaceutical companies and research institutions for data collection and monitoring.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based B2B pricing for healthcare systems |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
Acurable product offering
Product offeringCore offering
Acurable designs, manufactures, and sells the AcuPebble family of wearable medical devices that use proprietary acoustic sensing technology to record internal respiratory and cardiac biosignals via a neck-worn sensor. The signals are processed by automated cloud-based algorithms to produce clinically validated diagnostic reports for obstructive sleep apnoea (SA100, Ox100) and continuous monitoring for clinical research (RE100). The devices are sold to healthcare professionals, sleep clinics, NHS and other public health systems, and pharmaceutical and clinical research organizations across the UK, Europe, and the US.
Product overview
Acurable develops wearable medical devices based on proprietary acoustic sensing technology. The AcuPebble product family includes three products: AcuPebble SA100 (the CE-marked home sleep apnea testing device for Europe and UK), AcuPebble Ox100 (FDA-cleared version with 8-channel monitoring for the US market), and AcuPebble RE100 (research-focused device for clinical trials and remote patient monitoring). All devices use a non-invasive neck-worn acoustic sensor to record internal body sounds, which are processed by proprietary signal processing algorithms to automatically extract diagnostic parameters and generate sleep study reports.
Differentiator
Problem solved
Functional benefit
Brands
- AcuPebble: Family of wearable medical devices based on acoustic sensing technology for sleep apnoea diagnosis and respiratory/cardiac monitoring.
- AcuPebble SA100
- AcuPebble Ox100
- AcuPebble RE100
Products and services
- AcuPebble SA100 CE-marked wearable home sleep apnea testing device for fully remote automated diagnosis of Obstructive Sleep Apnoea. A non-invasive neck sensor records acoustic biosignals that are automatically analyzed to generate a clinically validated sleep report equivalent to ambulatory gold-standard polygraphy, with no patient training and no manual specialist interpretation. Sold to sleep clinics, NHS hospitals, and other healthcare professionals.
- AcuPebble Ox100 FDA-cleared multi-channel home sleep apnea testing device combining the AcuPebble neck sensor with a finger oximeter to produce a complete 8-channel sleep study report covering SpO2, cardiac signal, activity, respiratory phases, airflow, snoring, pulse rate, and body position. Targeted at the US sleep diagnostics market.
- AcuPebble RE100 Continuous monitoring device for breathing and cardiac biosignals used in clinical research and post-market surveillance. Enables remote capture of clinically validated physiological parameters and biomarkers without requiring patients to remain in clinical environments. Sold to pharmaceutical companies and contract research organizations.
Quantifiable outcome
- 94% positive predictive value and 98% negative predictive value compared to gold standard cardiorespiratory polygraphy (Royal Free Hospital trial, 150 patients)
- +7 more outcomes
Companies that use Acurable
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles3 records
Acurable technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Acurable partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered key, supporting and foundational.
- NyxoahkeyStrategic distribution agreement with Nyxoah to provide the AcuPebble SA100 home sleep test to the German market. This was announced alongside the Series A funding round.
- Microsoft ScaleUpsupportingInvited to join the Microsoft ScaleUp program for fast-growing start-ups in Europe in 2018. Provides access to Microsoft technology, resources, and network.
- Imperial College LondonfoundationalTechnology originated from over 10 years of research at Imperial College London's Wearable Technologies Lab, led by Prof. Esther Rodriguez-Villegas. IP was transferred to Acurable in 2016. Dr. Anas Imtiaz is also a research fellow at the Wearable Technologies Lab at Imperial College London.
- Royal Free Hospital NHS Foundation Trustkey150-patient powered clinical trial comparing AcuPebble SA100 to multi-channel polygraphy. Led by Dr Swapna Mandal. Trial proved diagnostic equivalence and 100% patient usability. Results published in BMJ Open.
- UCSF / MagnapkeyCalifornia-based Magnap used AcuPebble device in a sleep apnea clinical trial at the University of California San Francisco. Dr Michael Harrison (professor of surgery and pediatrics at UCSF) called AcuPebble 'game-changing' for enabling multiple night studies.
Scale indicators11 records
Recent moves10 records
Expansion highlights8 records
Acurable competitors and assessment
Company assessmentEmerging players
- Empatica: Empatica develops FDA-cleared medical-grade wearables (EpiMonitor for epilepsy, Embrace) using biosensors and cloud analytics. It is comparable as a peer medical-grade wearable company with cloud-based diagnostic algorithms and similar regulatory milestones.
- BioIntellisense: BioIntellisense produces the BioButton and BioSticker continuous remote monitoring wearables for vital signs and respiratory monitoring in hospitals and clinical trials. It overlaps with Acurable's clinical deterioration detection and pharma/CRO research use cases.
- Spire Health: Spire Health makes adhesive respiratory and sleep monitoring wearables for remote patient monitoring, including COPD and sleep apnea use cases. It overlaps with Acurable's RE100 research and remote monitoring positioning and targets similar enterprise healthcare customers.
Direct peers
- Nox Medical: Nox Medical manufactures the Nox T3 and related polysomnography and home sleep testing systems widely used by sleep clinics and research institutions. It is a direct competitor in the HSAT and PSG category and overlaps with AcuPebble's clinical research and diagnostic use cases.
- CleveMed: CleveMed produces the SleepScout and Sapphire PSG home sleep testing devices for sleep clinicians. It targets the same hospital and sleep lab customers as AcuPebble with portable PSG-class HSAT hardware.
- SOMNOmedics: SOMNOmedics is a German manufacturer of polysomnography and home sleep testing systems (SOMNOwatch, SOMNOscreen) used in European sleep medicine. It directly overlaps with AcuPebble in European clinical sleep diagnostics.
- Compumedics: Compumedics manufactures Somté and Siesta polysomnography and home sleep testing systems used by sleep clinics and research labs globally. It directly overlaps with AcuPebble's clinical diagnostic offering for sleep specialists.
- Itamar Medical (ZOLL Itamar, WatchPAT): Itamar Medical's WatchPAT is a leading FDA-cleared home sleep apnea testing device and the most direct competitor to AcuPebble SA100 in clinical-grade automated OSA diagnosis. Now part of ZOLL/ResMed, it competes head-to-head with AcuPebble for sleep clinic and cardiology channel accounts.
Broad incumbents
- Philips Respironics: Philips Respironics offers Alice NightOne and other home sleep testing devices alongside its market-leading CPAP portfolio. As a broad incumbent in sleep medicine, it competes with AcuPebble on diagnostic workflows within hospital systems.
- ResMed: ResMed is the global leader in sleep apnea and respiratory care with CPAP/APAP therapy devices, masks, and increasingly home sleep diagnostics (via its ZOLL/Itamar acquisition). It is the dominant incumbent whose installed base and reimbursement infrastructure Acurable must compete against.
Market position
Strengths1 record
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Acurable social profiles
Digital presenceAcurable compliance and trust
Trust signalCompliance6 records
Acurable financial estimates
Financial estimateRevenue estimate
Valuation estimate
Acurable leadership team
Management profileNumber of profiles
Profiles3 records
Acurable funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Acurable M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Acurable
What does Acurable do?
Acurable designs, manufactures, and sells the AcuPebble family of wearable medical devices that use proprietary acoustic sensing technology to record internal respiratory and cardiac biosignals via a neck-worn sensor. The signals are processed by automated cloud-based algorithms to produce clinically validated diagnostic reports for obstructive sleep apnoea (SA100, Ox100) and continuous monitoring for clinical research (RE100). The devices are sold to healthcare professionals, sleep clinics, NHS and other public health systems, and pharmaceutical and clinical research organizations across the UK, Europe, and the US.
Is Acurable a public or private company?
Acurable is a private company. It is classified as venture growth investor backed and is currently operating.
When was Acurable founded?
Acurable was founded in 2016. It employs 11 to 50 people.
Where is Acurable based?
Acurable is headquartered in London, United Kingdom, in the Europe region.
How does Acurable make money?
Three revenue lines are on record. AcuPebble SA100 / Ox100 device sales are the primary driver. The others are cloud-based automated diagnosis service and clinical research and post-market surveillance (RE100).
Who are Acurable's main competitors?
Emerging players on record are Empatica, BioIntellisense and Spire Health. Direct peers are Nox Medical, CleveMed, SOMNOmedics, Compumedics and Itamar Medical (ZOLL Itamar, WatchPAT). Broad incumbents are Philips Respironics and ResMed.
Does Acurable have an API?
No public API is recorded for Acurable.
What industry is Acurable in?
Acurable's product category is Sleep Apnea Diagnostic Devices. Its primary akta.pro industry code is HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables), with a secondary code of HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration). Its NAICS code is 334510 and its SIC code is 3845.